Detalles de la búsqueda
1.
Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review.
Medicina (Kaunas)
; 60(3)2024 Feb 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38541111
2.
The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.
Medicina (Kaunas)
; 59(6)2023 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37374302
3.
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study.
Ann Clin Microbiol Antimicrob
; 21(1): 51, 2022 Nov 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36403020
4.
The Evaluation of Tau Deposition with [18F]PI-2620 by Using a Semiquantitative Method in Cognitively Normal Subjects and Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Mol Imaging
; 2021: 6640054, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34381315
5.
Effect of enhanced external counterpulsation treatment on renal function in cardiac patients.
BMC Nephrol
; 14: 193, 2013 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-24021027
6.
The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial).
J Infect Public Health
; 16(12): 2010-2016, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37890224
7.
Protection of inactivated vaccine against SARS-CoV-2 infections in patients with comorbidities: a prospective cohort study.
Front Med
; 17(5): 867-877, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37434065
8.
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab).
Microbiol Spectr
; 11(6): e0325723, 2023 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37975699
9.
Basis to Aid Crisis: Favipiravir Oral Solution for Hospital Compounding During COVID-19 Drug Shortage.
J Pharm Sci
; 112(2): 610-617, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36334809
10.
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
Int J Infect Dis
; 134: 211-219, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37393041
11.
Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial).
Phytomedicine
; 119: 155018, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37625206
12.
Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV).
Sci Rep
; 13(1): 14884, 2023 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37689754
13.
Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers.
Clin Pharmacol Drug Dev
; 12(1): 14-20, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35877195
14.
Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).
Int J Infect Dis
; 124: 190-198, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36180032
15.
Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline.
Vaccines (Basel)
; 10(2)2022 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35214725
16.
Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.
Vaccine
; 40(12): 1761-1767, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35210118
17.
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
Hum Vaccin Immunother
; 18(1): 2035573, 2022 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35240945
18.
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Expert Rev Vaccines
; 21(12): 1873-1881, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35792752
19.
SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand.
Public Health Pract (Oxf)
; 4: 100341, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36373034
20.
Comparison of performance between an F 18 -FDG PET normal brain template and a commercial template using the MIMneuro software.
J Med Imaging (Bellingham)
; 9(6): 064501, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36388144